Raymond James Financial
ZVRA icon

Raymond James Financial’s Zevra Therapeutics ZVRA Stock Holding History

Raymond James Financial’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$217K Sell
23,231
-2,420
-9% -$21.8K ﹤0.01% 4850
2025
Q4 		$230K Buy
25,651
+2,345
+10% +$22.2K ﹤0.01% 4725
2025
Q3 		$222K Sell
23,306
-3,610
-13% -$36.2K ﹤0.01% 4576
2025
Q2 		$237K Hold
26,916
– – ﹤0.01% 4431
2025
Q1 		$202K Hold
26,916
– – ﹤0.01% 4425
2024
Q4 		$224K Buy
+26,916
New +$230K ﹤0.01% 4339

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Raymond James Financial's ZVRA Position: Q1 2026 in Review

Raymond James Financial reduced its Zevra Therapeutics (ZVRA) stake by 9.4% in Q1 2026, selling an estimated $21.8K and leaving 23,231 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #4850.

Raymond James Financial first reported a position in ZVRA in Q4 2024 and has held it in 6 quarters since. The position peaked at $237K in Q2 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Raymond James Financial held 23,231 shares of Zevra Therapeutics worth $217K as of Q1 2026.
  • Raymond James Financial sold 2,420 Zevra Therapeutics shares in Q1 2026, an estimated $21.8K.
  • Zevra Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4850 holding.
  • Raymond James Financial first reported a position in Zevra Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Zevra Therapeutics position peaked at $237K in Q2 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.